Bloomberg reports that “The European debut of a pill to treat children with attention deficit hyperactivity disorder faces a major hurdle: convincing people the condition exists,” as Shire seeks to extend its market through the introduction of its ADHD medication Vyvanse to eight European countries. ““There’s been a great deal of resistance to even believing there is a disease,” said the president of the European Brain Council, a non-profit representing doctors, patients and companies that work on neurology and psychiatry issues. “Parents are loath to get their child labeled. Children are easy or difficult, that’s the diagnosis in society.”
Posted on: Wed, 02 Oct 2013 17:22:12 +0000